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Phenotypic assays are tools essential for drug discovery. Phenotypic assays have different
types of endpoints depending on the goals; (1) empirical endpoints for basic research to
understand the underlying biology that will lead to identiﬁcation of translation biomarkers,
(2) empirical endpoints to identify undesired effects related to toxicity of drug candidates,
and (3) knowledge-based endpoints (biomarkers) for drug discovery which ideally are
translational biomarkers that will be used to identify new drug candidates and their
corresponding molecular mechanisms of action. The value of phenotypic assays is
increased through effective alignment of phenotypic assay endpoints with the objectives
of the relevant stage in the drug discovery and development cycle.
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INTRODUCTION
The goal of the paper is to provide awareness that a key feature
of phenotypic assays for drug discovery is the relationship of the
measured endpoint to a biomarker that translates to the desired
clinical response. In the early research phase phenotypic assays can
be used to increase understanding of the disease and to identify
potential translational biomarkers, while in the application phase
in which the underlying knowledge of the disease is translated to
treatments phenotypic assays should be aligned with translational
biomarkers. Examples of drug discovery strategies show that the
phenotypic endpoints for many of the successful strategies used
previous knowledge that effectively translated to clinical outcomes.
Phenotypic assays measure a phenotype in a physiological sys-
tem. The term “phenotypic assay” includes all preclinical assay
formats that use physiological systems, e.g., animals, cells, and
biochemical pathways. Phenotypic assays make few assumptions
as to the molecular details of how the system works and provide
an empirical method to probe effects in physiological systems. The
phenotypemost relevant to the practice of drug discovery is a phe-
notype that directly translated to the clinical disease (translational
biomarker).
Phenotypic assays have always played an important role in drug
discovery. Much of early pharmacology and drug discovery was
based on phenotypic assays. Phenotypic assays were used to iden-
tify leads that provided the desired efﬁcacy. In his nobel lecture
entitled “Selective inhibitors of dihydrofolate reductase” George
H. Hitchings Jr. stated “Those early, untargeted studies led to
the development of useful drugs for a wide variety of diseases
and has justiﬁed our belief that this approach to drug discovery
is more fruitful than narrow targeting”(Hitchings, 1988). In the
last decades of the 20th century the emphasis of drug discovery
changed to amore reductionist, target-based approach andpheno-
typic assays were primarily used to conﬁrm efﬁcacy and evaluate
safety. The hope was that the molecular and genetic revolution
Abbreviations: MMOA, molecular mechanism of action; PDD, phenotypic drug
discovery; TDD, target-based drug discovery.
would provide numerous new medicines due in part to the capa-
bilities to identify many new drug targets. Though not explicitly
stated, the idea was that the drug targets would be biomarkers
for the disease. Accordingly, a new paradigm of drug discovery
emerged in which the target was the biomarker for disease. In this
paradigm the central features are (1) identiﬁcation of a molecule
that binds to that target and (2) optimization of the biopharma-
ceutics properties such that the drug concentrations in the body are
sufﬁcient to ensure that thedrug is bound to the target through-out
the dosing interval. This target-based paradigm was envisioned to
provide a more rational approach to drug discovery, analogous
to a design and engineering approach. It is well documented that
this approach has not produced the desired results and in fact
productivity has dramatically decreased (Scannell et al., 2013).
Phenotypic assays in animals have always been required to eval-
uate the safety of a drug substance. In the last few years there has
been a reemergence of interest in using phenotypic assays to drive
discovery. Swinney and Anthony (2011) analyzed the discovery
strategies for new molecular entities (NMEs) that were approved
by the U.S. Food and Drug Administration (FDA) between 1999
and 2008. Of the 259 agents that were approved, 75 were ﬁrst-in-
class drugs with new molecular mechanism of action (MMOAs),
andout of these, 50 (67%)were smallmolecules and25 (33%)were
biologics. The results also showed that the contribution of phe-
notypic screening to the discovery of ﬁrst-in-class small-molecule
drugs exceeded that of target-based approaches—with 28 and 17
of these drugs coming from the two approaches, respectively—in
an era in which the major focus was on target-based approaches.
A more recently analysis by Swinney and Xia (2014) of the 102
NMEs approved between 1999 and 2012 for rare diseases showed
a similar trend of success with phenotypic strategies; for ﬁrst in
class NMEs there were 15 that used phenotypic drug discovery
(PDD), 12 that used target-based drug discovery (TTD) and 18
for biologics.
What is required to realize the full value of PDD in the 21st
century? There are many aspects that are important including
the quality of the assays, the sources of drug substance and the
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strategies to move compounds forward through development
despite incomplete knowledge of their mechanisms of action.
Another important feature is the choice and predictability of the
phenotypic endpoint, which is the focus of this short report.
THE DRUG DISCOVERY AND DEVELOPMENT CYCLE
The approval of a medicine to treat an unmet medical need
involves an iterative cycle of testing and learning. Figure 1
describes some of the important phases in the process. The pro-
cess of discovery and development of a new medicine is initiated
in response to an unmetmedical need to treat a disease. Physiolog-
ical, genetic, and chemical knowledge provide an understanding
of the disease. This knowledge will lead to the identiﬁcation of
translation biomarkers that are used to evaluate the effectiveness
of a potential medicine. This is the research phase (12–3 o’clock).
Phenotypic assays run in the research phase are extremely impor-
tant to the understanding of the underlying biology and to help
identify translational biomarkers.
The knowledge obtained in the research phase is used to
inform the discovery phase (3–6 o’clock). The available knowl-
edge informs drug discovery strategies which are used as starting
points for the practical process of discovering a new medicine.
TDD is associated withmodulating a speciﬁc gene product known
as the target, PDD is a strategy driven by assays which measure
phenotypes associated with the disease. Ideally these pheno-
types will be the associated with the translational biomarkers.
These two strategies are primarily focused on small molecules
and are medicinal chemistry intensive, in contrast to biologics
which use recombinant proteins and antibodies as therapeutics.
It should be noted that the knowledge to choose a strategy is
generally incomplete, however the more iterations that occur
in the drug discovery/development cycle the more complete the
knowledge and the better chance that a molecule will make
it to registration. The discovery strategies will result in a lead
molecule, ideally with activity against the translational biomarker.
The molecule will work by a MMOA that provides an opti-
mal therapeutic index. These molecules will then be optimized
for biopharmaceutics properties and safety to provide a drug
candidate. At this point the process of drug discovery is com-
plete and the molecule should succeed or fail based on its own
merit.
The left hand of the circle (from 6 to 12 o’clock) is the devel-
opment phase of drug discovery which involves testing for safety
and efﬁcacy in humans leading to registration. Multiple iterations
are generally required before a medicine with sufﬁcient efﬁcacy at
a safe dose is discovered, tested in humans, and registered.
HYPOTHESIS, MMOA, AND BIOMARKERS
Phenotypic assays have always been required to evaluate safety
and recently, their value to identify efﬁcacious molecules and their
mechanisms of action for ﬁrst-in-class medicines has been reeval-
uated (Swinney and Anthony, 2011; Kotz, 2012; Lee et al., 2012;
Lee and Berg, 2013; Swinney, 2013a; Swinney and Xia, 2014). A
major challenge in the identiﬁcation of safemedicines is to identify
MMOAs that provide both sufﬁcient efﬁcacy and safety (Swinney
and Anthony, 2011; Swinney, 2011, 2013a). These MMOAs could
be thought of as “pharmacological hot spots.”Due to the dynamic
complexity of physiology both at themolecular and systems level it
is difﬁcult to a priori predict the exact interactions and molecules
that will elicit a safe, therapeutically useful response, Empirical
phenotypic assays provide an unbiased approach to identify the
“pharmacological hot spots.”
FIGURE 1 | Drug discovery research and development cycle.
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In our earlier work we noted that in the target-based approach,
drug discovery is generally hypothesis-driven, and in this case,
there are at least three hypotheses that must be correct to
result in a new drug (Swinney and Anthony, 2011). The ﬁrst
hypothesis applies to all discovery approaches: the hypoth-
esis that activity in the preclinical screens used to select a
drug candidate will translate effectively into clinically mean-
ingful activity in patients. The other two related hypotheses
are that the target selected is important in human disease and
that the MMOA of drug candidates at the target in ques-
tion is one that is capable of achieving the desired biological
response. Successful ﬁrst-in-class, TDD requires the time and
resources to investigate all three hypotheses, and in particular,
the importance of hypothesis-testing to identify an appropri-
ate MMOA may be an underappreciated challenge, that – if
neglected –could contribute to increased attrition for such
approaches. In other words, it is clearly difﬁcult to rationally
identify the speciﬁc molecular interactions, from all the poten-
tial dynamic molecular interactions, that will contribute to an
optimal MMOA. Thus the key biochemical nuances impor-
tant for translation of the molecular interaction between a
drug and the target to an optimal pharmacological response
could be missed with target-based approaches. One value of
the phenotypic approach is the unbiased identiﬁcation of the
MMOA.
PHENOTYPIC ASSAYS FOR DRUG DISCOVERY
The endpoints for phenotypic assays can be anything that can be
accurately measured and range from a systems end point such
as blood pressure and seizures, to speciﬁc biomarkers including
Table 1 | Discovery biomarkers for phenotypic assays of NMEs approved by US FDA between 1999 and 2008 (Swinney andAnthony, 2011).
Generic name Discovery biomarker/assay MMOA
Aripiprazole Dopamine sensitive assays in animals Partial agonist D2 receptor
Azacitidine Cell based assays show effects on differentiation Irreversible
Caspofungin Acetate Inhibition of glucan synthesis in vitro Non-competitive
Cilostazol Blood platelet aggregation Inhibitor
Cinacalcet Hydrochloride Increased in Ca+2 in bovine parathyroid cells Allosteric activator
Daptomycin Cytotoxicity in antimicrobia Unknown
Docosanol Viral infection assays Unknown
Ezetimibe Cholesterol lowering in animals Transporter slow kinetics
Fulvestrant Binding followed by animal studies Antagonist induced degradation
Levetiracetam Audiogenic seizure susceptible mice Unknown




Originally identiﬁed in early 1960s as anti-diabetic Uncompetitive fast kinetics
Miglustat Glycolipid biosynthesis in HL-60 cells Reversible inhibitor
Nateglinide Hypoglycemic effects in fasted normal mice Fast kinetics
Nelarabine Cell based assays required for activation Chain terminator
Nitazoxanide Antimicrobial Redox/irreversible
Nitisinone Compounds originally discovered in screening against
plants
Irreversible
Pemirolast Potassium IgE induced anaphylaxis in animals Unknown
Ranolazine Animal models Unknown
Retapamulin Antimicrobial assays against resistant organism Allosteric inhibitor
Ruﬁnamide Animal anticonvulsant Unknown
Sinecatechins/green tea
extract
No screening herbal/evaluated in humans Unknown
Sirolimus Screened in antimicrobial assays Conformation inhibition
Varenicline Focused approach culminating in animal assays Partial agonist Nicotinic receptor
Vorinostat Cell based assay/cytodifferentiation Enzyme inhibitor
Ziconotide Intra-cerebral injection into mice Ion channel equilibrium kinetics
Zonisamide Animals models of epilepsy Unknown
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blood cholesterol and glucose for hyperlipidemia and diabetes,
respectively. Current technologies in genomics and high content
analysis allow measurement of many different markers of activity.
For drug discovery it is important to understand and differentiate
if these markers are translational biomarkers related to the clinical
disease.
A closer look at the discovery biomarkers for the 28 NME’s
categorized as phenotypic in the analysis of how medicines were
discovered by Swinney and Anthony (2011) is shown in Table 1.
As previously reported 10 of the medicines were identiﬁed in ani-
mal studies (Swinney, 2013b). The phenotypic endpoints for the
studies were well correlated with clinical indications. Levetirac-
etam, ruﬁnamide, and zonisamidewere identiﬁed inwell-establish
models for anti-convulsant activity and aripiprazole in dopamine
dependent activity known to be associated with anti-psychotic
behavior. Ziconotide was discovered in a model for pain and
ranolazine in animal model measuring anti-anginal and anti-
ischaemic effects. The endpoints for ezetimibe, nateglinide, and
pemirolast were blood cholesterol, blood glucose, and cutaneous
anaphylaxis, respectively. Nitisinone is used to treat tyrosineamia
type 1 and was originally developed as a herbicide and repurposed
for the rare disease when safety studies demonstrated an effect
on tyrosine metabolism (Swinney and Anthony, 2011; Swinney,
2013b).
The phenotypic end points for those discovered using cell based
assays provide examples where cell death was used as the pheno-
typic marker. These included azacitidine, daptomycin, linezolid,
nelarabine, retapamulin, and sirulimus, all were approved for use
as either anti-infective or anti-cancer therapies. Vorinostat was
discovered by its ability to induce cytodifferentiation and growth
arrest. The phenotypic markers for docosanol and cilostazol were
viral replication and platelet aggregation, respectively. For the dis-
covery of varenicline mesolimbic dopamine levels were measured
and for fulvestrant the estrogenic effects.
The phenotypic marker for cinacalcet was an increase in cal-
cium [Ca+2] in bovine parathyroid cells. The investigators were
looking to agonize a calcium receptor. Miglustat was prepared
and tested to interfere with glycoprotein synthesis and was repur-
posed for the Gaucher’s disease, a glycosphingolipid storage
disorder.
The phenotypic readouts for all these NMEs were well val-
idated markers of physiological functions. Cell death, anti-
convulsant activity, calcium activation, platelet aggregation, viral
replication, blood cholesterol, and glucose levels all translate
to clinical disease. In the course of the iterative R&D cycle
these biomarkers have become validated translational mark-
ers used to align drug discovery with clinical development
(Figure 1).
FUTURE TRENDS
The goal of drug discovery is to identify medicines that can beneﬁt
patients at safe doses. The challenge to achieve this goal is to iden-
tify medicines that will be safe and efﬁcacious prior to testing in
human studies, in preclinical studies. Themajor point highlighted
in this short paper is the importance of translational biomarkers
for PDDand to point out the difference between phenotypic assays
that are used to investigate the underlying disease biology. Both
are important, the research assays can be used to identify transla-
tional biomarkers and the discovery assays apply this knowledge
to identify new medical treatments. There is a great need for vali-
dated translational biomarkers to guide drug discovery in order to
identify safe and effective medicines prior to clinical evaluation.
This is key to decreasing attrition and increasing productivity of
pharmaceutical research.
The reality is that the more relevant the system is to physiology
the better it will predict the clinical success. Associated with this
complexity is the feasibility of obtaining predictive information.
Phenotypic assays that translate effectively to human disease will
always be required for the reasons described above, including the
ability to identify an optimal MMOA and derisk safety. Unfortu-
nately predictive phenotypic assays and relevant biomarkers are
not available for most human diseases. One of the hopes for the
genetic revolution was to identify speciﬁc genotypes, genes, and
targets that could be used to guide preclinical drug discovery to
identify newmedicines. This approach has not been as widely suc-
cessful as hoped. Aligning these efforts to identify translational
biomarkers for phenotypic assays should increase the successful
discovery of new medicines.
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